1. Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients.
- Author
-
Koutake Y, Taniguchi J, Yasumori N, Nagaishi H, Eto T, Nakashima K, Fukazawa M, and Hayashi T
- Subjects
- Adult, Aged, Aged, 80 and over, Dasatinib adverse effects, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Retrospective Studies, Safety, Treatment Outcome, Young Adult, Dasatinib therapeutic use, Drug Interactions, Histamine H2 Antagonists therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Proton Pump Inhibitors therapeutic use
- Abstract
We evaluated the effect of proton pump inhibitors (PPIs) and H2-receptor antagonists (H2RAs) on the efficacy and safety of dasatinib for chronic-phase chronic myeloid leukemia (CP-CML). Retrospective analyses were performed for patients with CP-CML who received dasatinib at seven hospitals between April 2009 and December 2016. Seventy-three patients were identified, 16 of whom received PPIs or H2RAs concurrently with dasatinib. Major molecular response at 12 months was observed in 13 of 13 patients (100%) with concurrent PPIs or H2RAs (combination group), and in 23 of 51 patients (45.1%) who received only dasatinib (dasatinib-alone group; P < 0.001). Deep molecular response at 12 months was observed in four of six patients (66.7%) in the combination group, and seven of 38 patients (18.4%) in the dasatinib-alone group (P = 0.027). Dasatinib chemotherapy was stopped after 18 months for 25 patients (43.9%) from the dasatinib-alone group, but for none from the combination group. Combination treatment with PPIs or H2RAs did not reduce the efficacy of dasatinib. PPIs and H2RAs reduce the incidence of dasatinib discontinuation due to adverse events and increase the efficacy of dasatinib chemotherapy for patients.
- Published
- 2020
- Full Text
- View/download PDF